An exploratory phase II study of the combination of a tyrosine kinase inhibitor (STI571) [imatinib] and a pegylated human recombinant interferon alfa2b (PEGINTRON) [peginterferon alfa-2b] in the treatment of chronic myeloid leukemia in chronic phase.

Trial Profile

An exploratory phase II study of the combination of a tyrosine kinase inhibitor (STI571) [imatinib] and a pegylated human recombinant interferon alfa2b (PEGINTRON) [peginterferon alfa-2b] in the treatment of chronic myeloid leukemia in chronic phase.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Imatinib; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top